About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ATHX - Athersys| Previous Close | $1.83 | Open | $1.84 |
| Volume | 2.1M | Market Cap | 361.79M |
| Yield | Last Dividend |
| Athersys, Inc. (NASDAQ:ATHX) Insider Lau... | 12/18/20 |
| Athersys, Inc. (NASDAQ:ATHX) insider Laura K. Campbell sold 10,000 shares of the stock in a transaction dated Tuesday, December 15th. The shares were ... | |
| Lordstown Motors, Athersys projects are ... | 12/07/20 |
| Half of the projects approved Monday, Dec. 7, by the Ohio Tax Credit Authority are in Northeast Ohio, where nearly 3,000 new jobs are projected to be ... | |
| Athersys Inc. expands board of directors... | 11/16/20 |
| The clinical-stage regenerative medicine company in Cleveland said it has added Katherine Kalin, Baiju R. Shah and Jane Wasman as board members. It al... | |
| Athersys Announces Three Appointments to... | 11/16/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces three appointments to its board of directors, deepening board expertise to prepare ... | |
| Athersys shares third-quarter results, c... | 11/13/20 |
| The Cleveland biotechnology company has announced continued progress in clinical trials studying its MultiStem stem cell therapy. | |
| Athersys Reports Third Quarter 2020 Resu... | 11/09/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces Q3 earnings and initiation of MultiStem?? Phase 2 clinical trial in patients with t... | |
| Zacks Investment Research Lowers Athersy... | 10/24/20 |
| Zacks Investment Research cut shares of Athersys (NASDAQ:ATHX) from a hold rating to a sell rating in a research report released on Wednesday morning,... | |
| Athersys (NASDAQ:ATHX) Lowered to Sell a... | 10/23/20 |
| Athersys (NASDAQ:ATHX) was downgraded by Zacks Investment Research from a ???hold??? rating to a ???sell??? rating in a report released on Wednesday, ... | |
| Athersys (NASDAQ:ATHX) Lowered to ???Sel... | 10/21/20 |
| Athersys (NASDAQ:ATHX) was downgraded by Zacks Investment Research from a ???hold??? rating to a ???sell??? rating in a research note issued to invest... | |
| Athersys (NASDAQ:ATHX) and Trevena (NASD... | 10/21/20 |
| Athersys (NASDAQ:ATHX) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will compare the two com... | |
| Athersys (NASDAQ:ATHX) Trading Down 8.9% | 10/20/20 |
| Athersys, Inc. (NASDAQ:ATHX) traded down 8.9% on Tuesday . The company traded as low as $1.62 and last traded at $1.63. 3,206,430 shares were traded d... | |
| Tissue Regeneration Market Future Scope ... | 10/14/20 |
| The market insights gained through this Tissue Regeneration Market research analysis report facilitates more defined understanding of the market lands... | |
| Athersys to Host Third Quarter Financial... | 10/08/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results on Monday, Novembe... | |
| Athersys Reports Second Quarter 2020 Res... | 08/10/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planne... | |
| Athersys to Host Second Quarter Financia... | 07/20/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August... | |
| Athersys Announces Upcoming Presentation... | 05/18/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys taking a leading role at the International Society of Cell ad Gene Therapy Conference and will di... | |
| Athersys Reports First Quarter 2020 Resu... | 05/07/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Q1 Earnings reflects multiple achievements for the Company, including obtaining FDA authorization... | |
| Athersys Announces Commencement of Patie... | 05/05/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--The first patients have been enrolled in the Athersys COVID-19 induced ARDS clinical program using MultiSt... | |
| Athersys and University Hospitals Clevel... | 05/01/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--The first clinical site is now open for the MACOVIA study, a pivotal Phase 2/3 study evaluating MultiStem?... | |
| Athersys to Present at the Bank of Ameri... | 04/29/20 |
| CLEVELAND--(BUSINESS WIRE)--Athersys presentation scheduled for May 14, 2020 at 8:20 AM EDT. A live webcast will be available at https://tinyurl.com/y... | |
| Trump Demands Harvard Return Stimulus Mo... | 04/21/20 |
| Trump Demands Harvard Return Stimulus Money; Harvard Responds It Has No Idea What Trump Is Talking About The resentment against publicly-traded compan... | |
| Athersys Announces Closing of Public Off... | 04/20/20 |
| CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the closing of its previously announced underwritten public offer... | |
| Athersys Announces Pricing of Public Off... | 04/15/20 |
| CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the pricing of its previously announced underwritten public offer... | |
| Biocept To Begin COVID-19 Testing; BioCr... | 04/13/20 |
| As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, ... | |
| Athersys's stock shoots up after FDA OKs... | 04/13/20 |
| Shares of Athersys Inc. undefined shot up 26.5% in premarket trading Monday, after the company said it has received Food and Drug Administration??? | |
| FDA Authorizes Athersys to Initiate a Pi... | 04/13/20 |
| CLEVELAND--(BUSINESS WIRE)-- #ARDS--Company plans to initiate a Phase 2/3 pivotal study in patients with COVID-19 induced ARDS this quarter | |
| Cleveland biotech company making headway... | 04/01/20 |
| Athersys, a Cleveland biotech company, says it is making headway on a possible stem cell treatment for the COVID-19 virus. | |
| The Daily Biotech Pulse: InflaRx Begins ... | 04/01/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) At... | |
| Athersys Announces Financial Results for... | 03/16/20 |
| CLEVELAND--(BUSINESS WIRE)-- #ARDS--Clinical trial results in ARDS supported designation by BARDA as a "Highly Relevant" program for COVID-19 and othe... | |
| Athersys to Host Year-End 2019 Financial... | 02/10/20 |
| CLEVELAND--(BUSINESS WIRE)---- $ATHX--Athersys will host year-end 2019 financial results call on March 16, 2020. | |
| Date | 2020-11-09 (AMC) | Est. (EPS/Rev.) | ($0.09)/ 170K |
| Actual (EPS/Rev.) | $-0.11/ $86.00 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| FEAT. MARVIN GAYE | JOHN KROLIKOWSKI JR | 62.00 % | Subscribe |
| Mojo Day Trading | ProTrader Mike | 42.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
